Loxo Oncology (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $136.51, for a total transaction of $2,047,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
NASDAQ LOXO opened at $167.53 on Friday. The company has a market cap of $4.23 billion, a P/E ratio of -31.55 and a beta of 2.32. Loxo Oncology has a 52 week low of $138.92 and a 52 week high of $143.55.
Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. During the same quarter in the previous year, the company posted ($0.96) EPS. analysts forecast that Loxo Oncology will post 0.55 earnings per share for the current year.
Several equities research analysts have recently commented on LOXO shares. BidaskClub upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Morgan Stanley lowered shares of Loxo Oncology from an “overweight” rating to an “equal weight” rating and set a $103.00 price target for the company. in a report on Wednesday, March 21st. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Loxo Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 8th. BTIG Research restated a “buy” rating and issued a $156.00 price target on shares of Loxo Oncology in a report on Thursday. Finally, ValuEngine upgraded shares of Loxo Oncology from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and three have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $152.89.
A number of large investors have recently added to or reduced their stakes in LOXO. Quantbot Technologies LP grew its position in Loxo Oncology by 770.1% during the 1st quarter. Quantbot Technologies LP now owns 931 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 824 shares during the last quarter. IFP Advisors Inc grew its position in Loxo Oncology by 509.6% during the 1st quarter. IFP Advisors Inc now owns 1,012 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 846 shares during the last quarter. QS Investors LLC purchased a new stake in Loxo Oncology during the 4th quarter worth approximately $118,000. Xact Kapitalforvaltning AB purchased a new stake in Loxo Oncology during the 4th quarter worth approximately $208,000. Finally, Cambridge Investment Research Advisors Inc. grew its position in Loxo Oncology by 26.8% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 617 shares during the last quarter.
Loxo Oncology Company Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.